建立中国孤儿药品价值评估框架
Handong Chen1, Yuliang Xiang1,2, Xian Tang1
1West China School of Pharmacy, Sichuan University, 17 Renmin South Road (3rd Section), Chengdu, China.
Orphanet journal of rare diseases
|October 20, 2024
概括
这项研究开发了一种多标准决策分析 (MCDA) 框架,用于评估中国的孤儿药品. 对于评估孤儿药物价值和帮助医疗保险决策,MCDA方法是可行的.
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 决策科学 决策科学 决策科学
背景情况:
- 孤儿药品在中国面临着独特的价值评估挑战.
- 现有的框架可能无法完全捕捉到中国医疗保健系统的特定需求和背景.
研究的目的:
- 为中国的孤儿药品建立一个合适的价值评估框架.
- 为此目的,调整多标准决策分析 (MCDA) 方法.
主要方法:
- 系统的文献审查和EVIDEM框架的调整.
- 通过研讨会和专家咨询参与利益相关方.
- 使用权重和调查方法收集定量和质量数据.
主要成果:
- 制定了11个定量标准和8个定性标准的框架,以适应中国的国家条件.
- 两个阶段的百分点分布方法被选为权重标准.
- 通过对71名参与者的调查,公众的意见被纳入调查.
结论:
- 多标准决策分析 (MCDA) 是中国孤儿药物价值评估的一个可行的方法.
- 开发的框架可以补充医疗保险的药物获取决策.
- 为了中国的背景,建议进一步完善框架及其权重方法.
更多相关视频
04:24Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
Published on: June 16, 2023
1.4K
10:50Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
Published on: May 1, 2019
14.6K
相关概念视频
Prescription, Nonprescription and Orphan Drugs
699
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
699
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Preclinical Development: Overview
4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
Drug Nomenclature
1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
